From mild cognitive impairment to subjective cognitive decline: conceptual and methodological evolution

Yu-Wen Cheng,1 Ta-Fu Chen,2 Ming-Jang Chiu2,3 1Department of Neurology, National Taiwan University Hospital, Hsin-Chu Branch, Hsin-Chu, Taiwan; 2Department of Neurology, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan; 3Department of Psychology,...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Cheng YW, Chen TF, Chiu MJ
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	mild cognitive impairment (MCI) subjective cognitive decline (SCD) preclinical Alzheimer’s disease Alzheimer’s disease (AD) Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/4a0119aae05e4534a0f474a145146b0c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4a0119aae05e4534a0f474a145146b0c
record_format	dspace
spelling	oai:doaj.org-article:4a0119aae05e4534a0f474a145146b0c2021-12-02T11:12:52ZFrom mild cognitive impairment to subjective cognitive decline: conceptual and methodological evolution1178-2021https://doaj.org/article/4a0119aae05e4534a0f474a145146b0c2017-02-01T00:00:00Zhttps://www.dovepress.com/from-mild-cognitive-impairment-to-subjective-cognitive-decline-concept-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Yu-Wen Cheng,1 Ta-Fu Chen,2 Ming-Jang Chiu2,3 1Department of Neurology, National Taiwan University Hospital, Hsin-Chu Branch, Hsin-Chu, Taiwan; 2Department of Neurology, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan; 3Department of Psychology, College of Science, National Taiwan University, Taipei, Taiwan Abstract: Identification of subjects at the early stages of Alzheimer’s disease (AD) is fundamental for drug development and possible intervention or prevention of cognitive decline. The concept of mild cognitive impairment (MCI) evolved during the past two decades to define subjects at the transitional stage between normal aging and dementia. Evidence from cross-sectional and longitudinal studies has shown that MCI is associated with an increased risk of positive AD biomarkers and an increased annual conversion rate of 5%–17% to AD. The presence of AD biomarkers in subjects with MCI was associated with an even higher risk of progression to dementia. However, earlier clinical trials for pharmacotherapy in subjects with MCI were disappointing. To extend the spectrum of AD to an earlier stage before MCI, subjective cognitive decline (SCD) was introduced and was defined as self-reported cognitive decline before the deficits could be detected by cognitive tests. Subjects with SCD have an increased risk of underlying AD pathology. However, SCD can also develop secondary to other heterogeneous etiologies, including other neurodegenerative and psychiatric diseases, personality traits, physical conditions, and medication use. Several clinical and biomarker features were proposed to predict risk of conversion to AD in subjects with SCD. Further longitudinal studies are needed to support the validity of these high-risk features. Keywords: mild cognitive impairment, subjective cognitive decline, preclinical Alzheimer’s disease, Alzheimer’s diseaseCheng YWChen TFChiu MJDove Medical Pressarticlemild cognitive impairment (MCI)subjective cognitive decline (SCD)preclinical Alzheimer’s diseaseAlzheimer’s disease (AD)Neurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 13, Pp 491-498 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	mild cognitive impairment (MCI) subjective cognitive decline (SCD) preclinical Alzheimer’s disease Alzheimer’s disease (AD) Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	mild cognitive impairment (MCI) subjective cognitive decline (SCD) preclinical Alzheimer’s disease Alzheimer’s disease (AD) Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Cheng YW Chen TF Chiu MJ From mild cognitive impairment to subjective cognitive decline: conceptual and methodological evolution
description	Yu-Wen Cheng,1 Ta-Fu Chen,2 Ming-Jang Chiu2,3 1Department of Neurology, National Taiwan University Hospital, Hsin-Chu Branch, Hsin-Chu, Taiwan; 2Department of Neurology, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan; 3Department of Psychology, College of Science, National Taiwan University, Taipei, Taiwan Abstract: Identification of subjects at the early stages of Alzheimer’s disease (AD) is fundamental for drug development and possible intervention or prevention of cognitive decline. The concept of mild cognitive impairment (MCI) evolved during the past two decades to define subjects at the transitional stage between normal aging and dementia. Evidence from cross-sectional and longitudinal studies has shown that MCI is associated with an increased risk of positive AD biomarkers and an increased annual conversion rate of 5%–17% to AD. The presence of AD biomarkers in subjects with MCI was associated with an even higher risk of progression to dementia. However, earlier clinical trials for pharmacotherapy in subjects with MCI were disappointing. To extend the spectrum of AD to an earlier stage before MCI, subjective cognitive decline (SCD) was introduced and was defined as self-reported cognitive decline before the deficits could be detected by cognitive tests. Subjects with SCD have an increased risk of underlying AD pathology. However, SCD can also develop secondary to other heterogeneous etiologies, including other neurodegenerative and psychiatric diseases, personality traits, physical conditions, and medication use. Several clinical and biomarker features were proposed to predict risk of conversion to AD in subjects with SCD. Further longitudinal studies are needed to support the validity of these high-risk features. Keywords: mild cognitive impairment, subjective cognitive decline, preclinical Alzheimer’s disease, Alzheimer’s disease
format	article
author	Cheng YW Chen TF Chiu MJ
author_facet	Cheng YW Chen TF Chiu MJ
author_sort	Cheng YW
title	From mild cognitive impairment to subjective cognitive decline: conceptual and methodological evolution
title_short	From mild cognitive impairment to subjective cognitive decline: conceptual and methodological evolution
title_full	From mild cognitive impairment to subjective cognitive decline: conceptual and methodological evolution
title_fullStr	From mild cognitive impairment to subjective cognitive decline: conceptual and methodological evolution
title_full_unstemmed	From mild cognitive impairment to subjective cognitive decline: conceptual and methodological evolution
title_sort	from mild cognitive impairment to subjective cognitive decline: conceptual and methodological evolution
publisher	Dove Medical Press
publishDate	2017
url	https://doaj.org/article/4a0119aae05e4534a0f474a145146b0c
work_keys_str_mv	AT chengyw frommildcognitiveimpairmenttosubjectivecognitivedeclineconceptualandmethodologicalevolution AT chentf frommildcognitiveimpairmenttosubjectivecognitivedeclineconceptualandmethodologicalevolution AT chiumj frommildcognitiveimpairmenttosubjectivecognitivedeclineconceptualandmethodologicalevolution
_version_	1718396107704238080

From mild cognitive impairment to subjective cognitive decline: conceptual and methodological evolution

Ejemplares similares